JWH-072

JWH-072

File:JWH-072 structure.png
IUPAC Name:	{{{IUPACName}}}
Other Names:
Identifiers
CAS Number
PubChem
ChemSpider
SMILES
InChI
InChIKey
StdInChI
StdInChIKey
Properties
Chemical formula	CHNO
Appearance
Density
Melting Point
Boiling Point
Solubility
Hazards
Main Hazards
Flash Point
Autoignition Temperature

JWH-072 is a synthetic cannabinoid that acts as a potent agonist at both the CB1 and CB2 receptors. It is part of the naphthoylindole family of synthetic cannabinoids, which were originally developed for research purposes but have since been used recreationally.

Chemical Structure and Properties

JWH-072 is chemically classified as a naphthoylindole, which is a subclass of synthetic cannabinoids. Its chemical structure is characterized by a naphthalene group attached to an indole core. The full IUPAC name is (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol.

Pharmacology

JWH-072 acts as a full agonist at the CB1 and CB2 receptors, which are part of the endocannabinoid system. This system is involved in regulating a variety of physiological processes including mood, memory, appetite, and pain sensation. The binding affinity of JWH-072 for the CB1 receptor is similar to that of THC, the primary psychoactive component of cannabis.

Legal Status

Due to its psychoactive effects and potential for abuse, JWH-072 has been classified as a controlled substance in many countries. In the United States, it is listed as a Schedule I substance under the Controlled Substances Act, meaning it is illegal to manufacture, buy, possess, or distribute without a DEA license.

Health Effects and Risks

The use of JWH-072, like other synthetic cannabinoids, can lead to a range of adverse health effects. These may include anxiety, paranoia, tachycardia, hypertension, hallucinations, and in severe cases, psychosis. The long-term health effects of JWH-072 are not well understood, but there is concern about its potential to cause addiction and other mental health issues.

Research and Development

JWH-072 was originally developed by Dr. John W. Huffman and his team at Clemson University as part of a series of compounds intended to study the structure-activity relationships of cannabinoids. These compounds have been used in scientific research to better understand the endocannabinoid system and to develop potential therapeutic agents.

Also see

• Synthetic cannabinoids
• JWH-018
• Cannabinoid receptor
• Endocannabinoid system
• John W. Huffman